Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN SODIUM CHLORIDE 0 45 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN SODIUM CHLORIDE 0 45 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (factor Xa), and to a lesser extent factors IXa, XIa, and XIIa, thereby preventing thrombus formation and extension.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
IV: Initial bolus of 80 units/kg, then 18 units/kg/hour continuous infusion. Adjust based on aPTT. Typical maintenance: 1300 units/hour for adult (70 kg).
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Mean 1-2 hours (dose-dependent: increases with dose due to saturable clearance; at 100 U/kg IV: ~1 hr; at 400 U/kg: ~2.5 hrs); clinical context: may be prolonged in hepatic/renal disease
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal (primarily via saturable mechanism; small amount metabolized by liver and reticuloendothelial system; no biliary/fecal elimination of significance)
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte